Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$4.90 USD
-0.10 (-2.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.90 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Foghorn Therapeutics Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
FHTX 4.90 -0.10(-2.00%)
Will FHTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates
NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
Other News for FHTX
FHTX: Upcoming Virtual Meeting Hosted by B. Riley
Foghorn Therapeutics management to meet virtually with B. Riley
Foghorn Therapeutics reports Q2 results
Foghorn Therapeutics Inc (FHTX) Q2 2025 Earnings: EPS of -$0.33 Meets Estimates, Revenue of $7. ...
FHTX Reports Strong Q2 Revenue and Advances Cancer Treatment Pipeline